Grail grabs $900M-plus in Se­ries B; Al­ny­lam’s givosir­an makes PRIME time

→ Men­lo Park, CA-based Grail has banked more than $900 mil­lion in its first close of a big Se­ries B led by Arch Ven­ture Part­ners. J&J In­no­va­tion made a big con­tri­bu­tion, drawn by the up­starts plans to rev­o­lu­tion­ize the ear­ly de­tec­tion and treat­ment of can­cer. “We en­vi­sion a glob­al com­mu­ni­ty that ben­e­fits from ear­ly-stage can­cer de­tec­tion where few­er in­di­vid­u­als face the an­guish of late-stage di­ag­no­sis and dev­as­tat­ing out­comes,” said Jeff Hu­ber, Grail’s CEO. “I be­lieve that Grail’s ap­proach lever­ag­ing high-in­ten­si­ty se­quenc­ing, pop­u­la­tion-scale clin­i­cal stud­ies, and state of the art Com­put­er Sci­ence and Da­ta Sci­ence is un­par­al­leled in the field of can­cer de­tec­tion. Our team made tremen­dous progress in 2016 and I look for­ward to ad­di­tion­al clin­i­cal and strate­gic mile­stones.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.